IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism

Journal of Clinical Investigation

Volumn 110, Issue 10, 2002, Pages 1515-1523

  Malmberg, Karl Johan ^a   Levitsky, Victor ^b   Norell, Håkan ^a   De Matos, Cristina Teixeira ^b   Carlsten, Mattias ^a   Schedvins, Kjell ^c   Rabbani, Hodjattallah ^a   Moretta, Alessandro ^d   Söderström, Kalle ^b   Levitskaya, Jelena ^a   Kiessling, Rolf ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CD94 ANTIGEN; CELL RECEPTOR; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA E ANTIGEN; HLA G ANTIGEN; LECTIN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2A; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREGULATION; NATURAL KILLER CELL; OVARY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL; TUMOR IMMUNITY;

EID: 0036855636     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215564     Document Type: Article

References (52)

1. Shankaran, V., et al. 2001. IFN gamma and lymphocytes prevent primary rumour development and shape rumour immunogenicity. Nature. 410:1107-1111.
2. Kaplan, D.H., et al. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA. 95:7556-7561.
3. Dighe, A.S., Richards, E., Old, LJ., and Schreiber, R.D. 1994. Enhanced in vivo growth and resistance to rejection of minor cells expressing dominant negative IFN gamma receptors. Immunity. 1:447-456.
4. Rock, K.L., and Goldberg A.L. 1999. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17:739-779.
5. Moretta, A., et al. 1996. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14:619-648.
6. Long, E.O., and Rajagopalan, S. 2000. HLA class I recognition by killer cell Ig-like receptors. Semin. Immunol. 12:101-108.
7. Lopez-Boter, M., Llano, M., Navarro, F., and Bellon, T. 2000. NK cell recognition of non-classical HLA class I molecules. Semin. Immunol. 12:109-119.
8. Carosella, E.D., Paul, P., Moreau, P., and Rouas-Freiss, N. 2000. HLA-G and HLA-E: Fundamental and pathophysiological aspects. Immunol. Today. 21:532-534.
9. Ibrahim, E.C., et al. 2001. Tumor-specific upregularion of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res. 61:6838-6845.
10. Lefebvre, S., et al. 2002. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 196:266-274.
11. Paul, P., et al. 1999. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 59:1954-1960.
12. Braud, V.M., et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 391:795-799.
13. Borrego, F., Ulbrecht, M., Weiss, E.H., Coligan, J.E., and Brooks, A.G. 1998. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187:813-818.
14. Lee, N., et al. 1998. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA. 95:5199-5204.
15. Lee, N., Goodlett, D.R., Ishitani, A., Marquardt, H., and Geraghty, D.E. 1998. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J. Immunol. 160:4951-4960.
16. Braud, V., Jones, E.Y., and McMichael, A. 1997. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27:1164-1169.
17. Lopez-Botet, M., et al. 2000. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum. Immunol. 61:7-17.
18. McMahon, C.W., and Raulet, D.H. 2001. Expression and function of NK cell receptors in CD8+ T cells. Curr. Opin. Immunol. 13:465-470.
19. Guerra, N., et al. 2000. Killer inhibitory receptor (CD158b) modulates the lyric activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood. 95:2883-2889.
20. Speiser, D.E., et al. 1999. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med. 190:775-782.
21. Ikeda, H., et al. 1997. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunol. 6:199-208.
22. Moser, J.M., Gibbs, J., Jensen, P.E., and Lukacher, A.E. 2002. CD94-NKG2A receptors regulate antiviral CD8+ T cell responses. Nat. Immunol. 3:189-195.
23. Vance, R.E., Kraft, J.R., Altman, J.D., Jensen, P.E., and Raulet, D.H 1998. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatability complex (MHC) class I molecule Qa-1(b). J. Exp. Med. 188:1841-1848.
24. Ioannides, C.G., et al. 1991. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res. 51:4257-4265.
25. Rabinowich, H., et al. 1998. Lymphocyte apoprosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101:2579-2588.
26. Colonna, M., et al. 1997. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 186:1809-1818.
27. Levitsky, V., de Campos-Lima, P.O., Frisan, T., and Masucci, M.G. 1998. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J. Immunol. 161:594-601.
28. Heid, C.A., Stevens, J., Livak, K.J., and Williams, P.M. 1996. Real time quantitative PCR. Genome Res. 6:986-994.
29. Fink, L., et al. 1998. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat. Med. 4:1329-1333.
30. Sivori, S., et al. 1996. CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: Identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. Eur. J. Immunol. 26:2487-2492.
31. Gronberg, A., Ferm, M., Tsai, L., and Kiessling, R. 1989. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells. Cell. Immunol. 118:10-21.
32. Mingari, M.C., et al. 1995. Cytolytic T lymphocytes displaying natural killer (NK)-like activity: Expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Int. Immunol. 7:697-703.
33. Llano, M., et al. 1998. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: Preferential response to an HLA-G-derived nonamer. Eur. J. Immunol. 28:2854-2863.
34. Lee, N., et al. 1993. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity. 3:591-600.
35. Speiser, D.E., et al. 1999. CD28-negative cytolytic effector T cells frequently express NK receptors and are present ar variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur. J. Immunol. 29:1990-1999.
36. Mingari, M.C., et al. 1998. HLA class I-specific inhibitory receptors in human T lymphocytes: Interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc. Natl. Acad. Sci. USA. 95:1172-1177.
37. Bertone, S., et al. 1999. Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur. J. Immunol. 29:23-29.
38. Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:708-712.
39. Le Drean, E., et al. 1998. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: Association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phospharases. Eur. J. Immunol. 28:264-276.
40. Mingari, M.C., Moretta, A., and Moretra, L. 1998. Regulation of KIR expression in human T cells: A safety mechanism that may impair protective T-cell responses. Immunol. Today 19:153-157.
41. Young, N.T., Uhrberg, M., Phillips, J.H., Lamer, L.L., and Parham, P. 2001. Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J. Immunol. 166:3933-3941.
42. Vely, F., et al. 2001. Regulation of inhibitory and activating killer-cellig-like receptor expression occurs in T cells after termination of TCR rearrangements. J. Immunol. 166:2487-2494.
43. Gustafson, K.S., and Ginder, G.D. 1996. Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STATlalpha to a distinct interferon-gamma-responsive element. J. Biol. Chem. 271:20035-20046.
44. Cerboni, C., et al. 2001. Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur. J. Immunol. 31:2926-2935.
45. Vales-Gomez, M., Reyburn, H.T., Erskine, R.A., Lopez-Botet, M., and Strominger, J.L. 1999. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 18:4250-4260.
46. Navarro, F., et al. 1999. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules coexpressed on target cells. Eur. J. Immunol. 29:277-283.
47. Real, L.M., et al. 1999. Expression ofHLA G in human tumors is not a frequent event. Int. J. Cancer. 81:512-518.
48. Marincola, F.M., Jaffee, E.M., Hicklin, D.J., and Ferrone, S. 2000. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv. Immunol. 74:181-273.
49. Freedman, R.S., et al. 2000. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin. Cancer Res. 6:2268-2278.
50. Meyskens, F.L., Jr., et al. 1995. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group study. J. Natl. Cancer Inst. 87:1710-1713.
51. Pisa, P., et al. 1992. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. USA. 89:7708-7712.
52. Koh, C.Y., et al. 2001. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood. 97:3132-3137.